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Abstract
 
The adenylate cyclase toxin (CyaA) of 
 
Bordetella pertussis
 
 is a major virulence factor required for
the early phases of lung colonization. It can invade eukaryotic cells where, upon activation by
endogenous calmodulin, it catalyzes the formation of unregulated cAMP levels. CyaA intoxi-
cation leads to evident toxic effects on macrophages and neutrophils. Here, we demonstrate
that CyaA uses the 
 
a
 
M
 
b
 
2
 
 integrin (CD11b/CD18) as a cell receptor. Indeed, the saturable
binding of CyaA to the surface of various hematopoietic cell lines correlated with the presence
of the 
 
a
 
M
 
b
 
2
 
 integrin on these cells. Moreover, binding of CyaA to various murine cell lines
and human neutrophils was specifically blocked by anti-CD11b monoclonal antibodies. The
increase of intracellular cAMP level and cell death triggered by CyaA intoxication was also spe-
cifically blocked by anti-CD11b monoclonal antibodies. In addition, CyaA bound efficiently
and triggered intracellular cAMP increase and cell death in Chinese hamster ovary cells trans-
fected with 
 
a
 
M
 
b
 
2 
 
(CD11b/CD18) but not in cells transfected with the vector alone or with the
 
a
 
X
 
b
 
2 
 
(CD11c/CD18) integrin. Thus, the cellular distribution of CD11b, mostly on neutro-
phils, macrophages, and dendritic and natural killer cells, supports a role for CyaA in disrupting
the early, innate antibacterial immune response.
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Introduction
 
Bordetella pertussis
 
, the causative agent of whooping cough,
secretes several toxins, including the well known pertussis
toxin and the adenylate cyclase toxin, CyaA. In the murine
respiratory model, CyaA is a critical virulence factor re-
quired for the early steps of lung colonization. Indeed, gen-
etic deletion of the structural gene encoding for this toxin
dramatically decreases the pathological effects of 
 
B. pertussis
 
infection, reducing the number of bacteria recovered from
the lung and almost abolishing the inflammatory cell recruit-
ment and lung lesions observed after infection (1–6). More-
over, CyaA is able to induce a protective immunity against
 
B. pertussis
 
 infection in the murine respiratory model (7–10).
Originally discovered by Hewlett and Wolff (11) in 
 
B.
pertussis
 
 culture supernatants, the adenylate cyclase was later
found to be activated by the eukaryotic calmodulin (12).
This striking feature quickly found a rationale when it was
shown that the adenylate cyclase can enter into eukaryotic
cells where, upon activation by calmodulin, it triggers a
large increase in cAMP levels (13).
The CyaA toxin is encoded by the
 
 cyaA
 
 gene, and its ex-
pression, like that of other virulence genes of 
 
B. pertussis
 
, is
coordinately regulated by environmental signals through a
two-component system called BvgAS. The
 
 cyaA
 
 gene is
part of an operon that also contains the genes 
 
cyaB
 
,
 
 
 
-
 
D
 
, and
-
 
E
 
, required for
 
 
 
CyaA secretion (14).
The CyaA toxin is a bifunctional protein of 1,706 resi-
dues consisting of an NH
 
2
 
-terminal catalytic domain of 400
amino acids and a COOH-terminal part with 1,306 resi-
dues. This last domain is required for the binding of the
toxin to the target cell membrane and subsequent delivery
of the catalytic moiety into the cell cytosol (14). This
COOH-terminal part also exhibits a weak hemolytic activ-
ity because of its ability to form cation-selective channels in
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biological membranes (15–17). It is homologous to 
 
Esche-
richia coli
 
 hemolysin (HlyA) and other members of the RTX
(repeat in toxin) family of bacterial toxins. In particular, it
contains a series of glycine- and aspartate-rich nonapeptide
repeats that are involved in calcium binding (18, 19).
The CyaA polypeptide is synthesized as an inactive pro-
toxin that is converted to an active toxin by posttransla-
tional palmitoylation of two internal lysines (lysines 856
and 963). This modification requires the product of an ac-
cessory gene, 
 
cyaC
 
, which is located near 
 
cyaA
 
 on the 
 
B.
pertussis 
 
chromosome (20, 21).
CyaA has been shown to bind to and invade a variety of
cell types, including cells lacking membrane traffic like
mammalian erythrocytes (22). This suggests that the cata-
lytic domain of CyaA is directly translocated across the
plasma membranes of target cells. The internalization of the
catalytic domain into the cell cytosol is calcium and tem-
perature dependent and depends on the plasma membrane
potential (22–24). However, the molecular mechanisms by
which the toxin transports its NH
 
2
 
-terminal catalytic do-
main across the membrane remain largely unknown to
date. Furthermore, no specific receptor has yet been identi-
fied for CyaA binding.
The physiological consequences of cellular intoxication
by CyaA were characterized in vitro in phagocytes. Confer
and Eaton first showed that 
 
B. pertussis 
 
CyaA increases the
intracellular cAMP level in neutrophils or macrophages,
leading to an inhibition of chemotaxis and bacterial func-
tions such as phagocytic abilities and superoxide generation
(13). These properties were later confirmed with either pu-
rified toxins or bacterial mutants genetically deleted of
CyaA (25–27). On the contrary, and despite significant
changes in their cAMP content, the viability of cell lines
from nonhematopoietic origin appeared to be unaffected
by CyaA intoxication (6, 28). Moreover, we demonstrated
previously that 
 
B. pertussis
 
 CyaA can trigger macrophage
apoptosis in vitro (29, 30) and in vivo
 
 
 
(6). In these models,
genetic deletion of the 
 
cyaA
 
 gene abolished macrophage
apoptosis but not neutrophil death, suggesting that CyaA is
mainly responsible for macrophage apoptosis and might be
responsible for neutrophil apoptosis but that other factors
may also be involved. Besides that, in vivo studies per-
formed in a murine model of infection by 
 
B. bronchiseptica
 
,
which expresses a highly similar CyaA toxin, demonstrated
that the major target of 
 
B. bronchiseptica 
 
CyaA-induced tox-
icity is a GM-CSF–dependent and cyclophosphamide-sen-
sitive population that controls the early steps of infection
(31). These criteria identified neutrophils and possibly
other cells, including macrophages or dendritic cells. These
populations of target cells for CyaA are the same that limit
the early phases of infection, favoring the development of
an adaptative immune response that controls the later
phases of infection (31).
Thus, in contrast to numerous in vitro studies showing
that CyaA can enter a wide variety of cell lines, in vivo
studies strongly suggest that CyaA targets phagocytes such
as alveolar macrophages and neutrophils, representing a
major arm of 
 
B. pertussis
 
 against the innate immune system.
Since other members of the RTX toxin family bearing
cellular specificity for leukocytes have recently been shown
to bind to different receptors of the 
 
b
 
2
 
 integrin family (32–
34), we hypothesized that CyaA could similarly bind to
one of them. The 
 
b
 
2
 
 integrin family comprises four nonco-
valently linked 
 
a
 
/
 
b
 
 dimers sharing the same 
 
b
 
2
 
 chain but
harboring different 
 
a
 
 chains: 
 
a
 
L
 
b
 
2
 
 (CD11a/CD18, LFA-1),
 
a
 
M
 
b
 
2
 
 (CD11b/CD18, CR3, Mac1), 
 
a
 
X
 
b
 
2
 
 (CD11c/CD18,
p150/195), and the less well characterized 
 
a
 
D
 
/
 
b
 
2
 
 (CD11d/
CD18) (35). The expression of 
 
b
 
2
 
 integrins is restricted to
leukocytes. In mice, CD11a is expressed by all leukocytes;
CD11b is restricted to granulocytes/neutrophils, macro-
phages, myeloid dendritic cells, NK cells, and subsets of
CD8
 
1
 
 T cells and B cells, whereas CD11c is restricted to
dendritic cells (35, 36).
In this study, we demonstrate that CyaA binds specifi-
cally to target cells via the 
 
a
 
M
 
b
 
2
 
 integrin (CD11b/CD18)
and that this interaction is required for the intracellular de-
livery of the adenylate cyclase domain into leukocytes,
cAMP production, and CyaA-induced cell death.
 
Materials and Methods
 
Recombinant Toxins and Abs.
 
Protocol for CyaA production
has already been described elsewhere (23). CyaA toxins were
produced in an 
 
E. coli
 
 BLR strain harboring an expression plas-
mid, pCACT3, which carries the 
 
cyaA
 
 structural gene encoding
CyaA under the lacUV5 promoter and the 
 
cyaC
 
 accessory gene
required for activation of the protoxin. After solubilization in 8 M
urea, 20 mM Hepes-Na, pH 7.5, CyaA was purified to 
 
.
 
95%
homogeneity (as judged by SDS-gel analysis; data not shown) by
sequential DEAE–Sepharose and phenyl-Sepharose. In some ex-
periments, CyaA was purified by chromatographies on calmodu-
lin affigel. A recombinant detoxified CyaA toxin, CACTE5-Cys-
OVA, harboring a unique cysteine inserted within the genetically
inactivated catalytic domain was constructed by inserting an ap-
propriate double strand oligonucleotide between the BsiwI and
KpnI sites of pCACT-OVA-E5. In the resulting protein,
CACTE5-Cys-OVA, the amino acid sequence ASCGSIINFEK-
LGT is inserted between residues 224 and 225 of CyaA, and the
LQ dipeptide is inserted between residues 188 and 189 (the latter
insertion abolishes the cAMP-synthetizing activity of CyaA; ref-
erence 15). The purified detoxified protein was labeled on its
unique Cys with the highly specific sulfhydryl reagent 
 
N
 
-(6-
[biotinamidohexyl])-3
 
9
 
-(2
 
9
 
-pyridyldithio) propionamide (biotin-
HPDP; Pierce Chemical Co.) according to the manufacturer’s
instructions. The biotinylated CyaA was repurified on DEAE–
Sepharose to remove the unreacted biotin-HPDP reagent. Toxin
concentrations were determined spectrophotometrically from the
adsorption at 280 nm using a molecular extinction coefficient of
142 M
 
2
 
1
 
 
 
3
 
 cm
 
2
 
1
 
 or using the Bio-Rad Laboratories protein as-
say system.
Purified mAbs specific for murine CD11a (2D7, rat IgG2a, 
 
k
 
),
murine and human CD11b (M1/70, rat IgG2b, 
 
k
 
), murine
CD11c (HL3, hamster 1, 
 
l
 
), murine CD18 (C71/16, rat IgG2a,
 
k
 
), and control (A95-1, or anti-CD16/32, 2.4G2, rat IgG2b, 
 
k
 
)
originated from BD PharMingen. Supernatants from anti–human
CD11b (44, mouse IgG2a, 
 
k
 
) and anti–human CD18 (TS/18,
mouse IgG1, 
 
k
 
) hybridoma were used at 1:2 dilution in blocking
experiments. Supernatant from an anti–murine CD11b (5C6, rat
IgG2b, 
 
k
 
) was a gift from G. Milon (Institut Pasteur) and was 
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used at 1:2 final dilution in binding inhibition assays. Anti-CyaA
polyclonal Abs were obtained from a rabbit immunized subcuta-
neously with purified CyaA. Immunoglobulins were precipitated
from immune serum by 33% ammonium sulfate. After centrifu-
gation, the pelleted proteins were resuspended in 20 mM Hepes-
Na, 150 mM NaCl, pH 7.5, and extensively dialyzed against the
same buffer. The Abs were then biotinylated by incubation with
biotin–amidocaproate 
 
N
 
-hydroxysuccinimide ester dissolved in
dimethyl sulfoxide (Sigma-Aldrich) for 130 min at room temper-
ature. 100 mM ethanolamine, pH 9.0, was added, and after 30
min of additional incubation, the mixture was extensively dia-
lyzed at 4
 
8
 
C against buffer C. Biotinylated Abs were stored at
 
2
 
20
 
8
 
C.
 
Cells and Culture Media.
 
EL4, J774A.1, LB27.4, and THP-1
were obtained from American Type Culture Collection and
were cultured in RPMI 1640 supplemented with 10% FCS, 100
U/ml penicillin, 100 
 
m
 
g/ml streptomycin, and 2 mM 
 
L
 
-glu-
tamine, with or without 5
 
 3 
 
10
 
2
 
5
 
 M 2-mercaptoethanol (com-
plete medium). Fetal mouse skin dendritic cells (FSDCs;
 
1
 
 refer-
ence 37) were cultured in complete medium, and D1 cells were
cultured as described (38). Chinese hamster ovary (CHO) cells
transfected for human CD11b/CD18 or CD11c/CD18 or trans-
fected with the vector only were obtained from D. Golenbock
(Boston University School of Medicine, Boston, MA) and cul-
tured in the presence of neomycin as described previously (39).
Human neutrophils were purified as described previously (40). In
some experiments, they were activated by preincubation with 2
 
m
 
M fMLP (
 
N
 
-formyl-met-leu-phe; Sigma-Aldrich) for 30 min
at 37
 
8
 
C.
 
CyaA Binding Assays.
 
All binding assays were performed in
DMEM 4.5 mg/ml glucose (Life Technologies) without serum
in 96-well culture plates (Costar). 2
 
 3 105 cells/well were incu-
bated for 20 min (at 4 or 378C depending on the experiments) in
a 200 ml final volume. In some experiments, EDTA or EGTA
(Sigma-Aldrich) was added at the indicated concentrations. In
other experiments, cells were preincubated for 20 min at 48C in
the presence of blocking mAbs in 100 ml final volume. The toxin
solution was added to the wells in the continuous presence of the
mAbs in a total volume of 200 ml at 48C. Plates were centrifuged
at 1,500 rpm for 5 min, and supernatants were removed. Cells
were incubated at 48C for 25 min with biotinylated anti-CyaA
rabbit polyclonal Abs (1:400 in DMEM; 50 ml/well) in the pres-
ence of a control (nonimmune or preimmune) rabbit serum as a
saturating agent (1:50).
After centrifugation and supernatant removal, cells were
stained with streptavidin–PE (BD PharMingen) at 1:300 dilution
(50 ml/well). After washing, cells were analyzed by flow cytome-
try on a FACStar™ (Becton Dickinson) in the presence of 5 mg/
ml propidium iodide. Gatings were done to exclude cell aggre-
gates and dead cells by propidium iodide exclusion. Experimental
points were fitted to a hyperbolic model D mean fluorescence in-
tensity (MFI) = Bmax 3 [CyaA]/(Kd 1 [CyaA]), with Bmax equal
to the percentage of maximal binding, using Prism software.
cAMP Assay. cAMP accumulation was measured by an Ag
competition immunoassay (41) in which the incubation medium
was composed of DMEM without serum but containing 4.5 mg/
ml glucose and 20 U/ml hexokinase. Hexokinase, which cata-
lyzes the ATP-dependent phosphorylation of glucose, was added
to deplete the extracellular medium of any traces of ATP, thus
preventing the extracellular synthesis of cAMP. Therefore, the
amount of cAMP measured is representative of the accumulation
of strictly intracellular cAMP. 5 3 105 cells were preincubated in
96-well plates in 100 ml/well with or without 10 mg/ml of spe-
cific mAbs at 48C for 1 h and then incubated at 378C for 20 min
with 5 mg/ml CyaA and with 10 mg/ml of specific mAbs when
present during the preincubation. For the dose–response effect of
CyaA, cells were directly incubated with the toxin at 0.05, 0.5, or
5 mg/ml for 20 min at 378C. After intoxication, cells were centri-
fuged at 2,500 rpm for 5 min. Samples were lysed with 100 ml of
0.1 N HCl, boiled for 5 min at 1208C, and neutralized with 100
ml of 0.125 M Tris and 0.2 M NaCl. Microtiter plates were
coated with a cAMP–BSA conjugate diluted at 1:4,000 in 0.1 M
Na2CO3, pH 9.5. They were washed twice in 0.1% PBS–Tween,
saturated for 1 h in 2% PBS–BSA, and washed five times with
0.1% PBS–Tween. The samples and the cAMP standard (Sigma-
Aldrich) were directly added to the plates coated with cAMP–
BSA conjugate and serially diluted with a 1:1 mixture of 0.1 N
HCl and 0.125 M Tris–0.2 M NaCl. Anti-cAMP rabbit Abs were
added at 1:2,500 in 2% PBS–BSA and incubated at 378C for 3 h.
Plates were washed five times with 0.1% PBS–Tween. Anti–rab-
bit Abs coupled to horseradish peroxidase (Amersham Pharmacia
Biotech) were added at 1:2,500 in 2% PBS–BSA, incubated at
378C for 1 h, and revealed using the classical peroxidase reaction.
Experimental points of the standard curve were fitted to a sig-
moid model using Prism software.
Toxicity Assay. Cell death was evaluated as described previ-
ously (29, 30). In brief, 105 cells were incubated for 24 h in a 96-
well plate in complete medium and washed once with serum-free
medium. All cell incubations were further performed in serum-
free medium. Dose–response effects were evaluated by directly
applying various concentrations of CyaA to CHO cells at 378C
for 4 h. For cytotoxicity inhibition, cells were preincubated at
48C for 1 h with or without 10 mg/ml of specific mAbs and then
incubated at 378C with 0.5 mg/ml CyaA for 2 h for J774A.1 cells
or with 5 mg/ml CyaA for 4 h for CHO cells and with 10 mg/ml
of specific mAbs when present during the preincubation. Cell ly-
sis was evaluated using the Cytotox 96™ assay (Promega), which
quantifies the amount of lactate dehydrogenase (LDH) released in
the medium by dying cells.
Results
Saturable Binding of CyaA Correlates with the Presence of
CD11b at the Surface of Target Cells. To characterize
CyaA cellular specificity toward a population of leukocytes,
we chose four representative murine cell lines expressing
various combinations of b2 integrins: D1, a splenic myeloid
dendritic cell line; J774A.1, a tumoral macrophage; EL4, a
T cell thymoma, and LB27.4, a B cell lymphoma. After a
20-min incubation with CyaA at 378C, binding of the
toxin to the cell surface was monitored by flow cytometry
using biotinylated anti-CyaA Abs and streptavidin-PE. Un-
der these conditions, we observed an efficient, dose-depen-
dent and saturable binding of CyaA to D1 and J774A.1
cells (Fig. 1 A). The affinity of CyaA for D1 and J774A.1
cells was high since the apparent Kd were 9.2 6 4.5 and
3.2 6 1.9 nM, respectively. Binding of CyaA to EL4 and
LB27.4 cells was also observed, but it was not saturable at
the concentrations tested and much lower than that ob-
served for J774 or D1.
1Abbreviations used in this paper: CHO; Chinese hamster ovary; FHA, fila-
mentous hemagglutinin; FSDC, fetal mouse skin dendritic cell; LDH, lac-
tate dehydrogenase; MFI, mean fluorescence intensity.1038 CyaA from Bordetella pertussis Binds to Cells via CD11b/CD18
To determine if the binding of CyaA to the D1 and J774
cell lines correlates with the expression of one of the mem-
bers of the b2 integrin family, we performed a phenotypic
analysis of these cells by flow cytometry using mAbs spe-
cific for the three a chains of the well-characterized b2 in-
tegrins (CD11a, CD11b, and CD11c) and for the common
b chain (CD18) (Fig. 1 B–E). D1 cells were strongly posi-
tive for CD11a, CD11b, CD11c, and CD18. J774A.1 cells
expressed mostly CD11b and CD18 but were also positive
for CD11a. EL4 cells and LB27.4 cells expressed mostly
CD11a and CD18. Taken together, these data show that
the efficient and saturable binding of CyaA to murine D1
Figure 1. Saturable binding of CyaA to different cell lines correlates with their CD11b expression. (A) CyaA binding at the surface of dendritic cells
(D1), macrophages (J774A.1), B cells (LB27.4), and T cells (EL4) was performed at 378C for 20 min. Surface-bound CyaA was detected by flow cytom-
etry using biotinylated anti-CyaA polyclonal Abs and streptavidin-PE. Binding is expressed as DMFI = (MFI value of cells incubated with CyaA) 2 (MFI
of cells without CyaA). (B–E) Cell-surface expression of b2 integrins on D1, J774A.1, LB27.4, and EL4 cells. CD11a (B), CD11b (C), CD11c (D), and
CD18 (E) expression was determined by flow cytometry using specific mAbs coupled to PE. Integrin expression is expressed as DMFI = (MFI value of
cells stained with specific mAb) 2 (MFI of cells stained with an isotype control mAb).
Figure 2. CyaA binding to murine cell lines is
blocked by anti-CD11b mAb. Cells were prein-
cubated at 48C for 15 min with or without 20
mg/ml of specific mAbs and then incubated at
48C for 20 min with 5 mg/ml CyaA and 10 mg/
ml of corresponding mAbs. Surface-bound
CyaA was detected with biotinylated anti-CyaA
polyclonal Abs, revealed by streptavidin-PE, and
analyzed by flow cytometry on living cells. (a–c)
Fluorescence histograms of D1 dendritic cells
were preincubated with medium alone (a), with
M1/70 anti-CD11b mAb (b), or with an iso-
type-matched rat IgG2b (c) and then incubated
with (gray) or without (white) CyaA in the pres-
ence or absence of mAbs. The cell number is
plotted against the log of PE fluorescence. (d–f)
D1 dendritic cells (d), FSDCs (e), or J774A.1
macrophages (f) were preincubated with me-
dium alone (s) or with M1/70 anti-CD11b
mAb (d), and then incubated with CyaA with
or without M1/70 anti-CD11b mAb. Bmax was
determined by fitting experimental points to
DMFI = Bmax 3 [CyaA]/(Kd 1 [CyaA]). Bind-
ing of CyaA is plotted as a percentage of Bmax
plotted against CyaA concentration. (g–i) Effect
of specific mAbs on the binding of a fixed dose
of CyaA. D1 (g), FSDCs (h), or J774A.1 (i) cells
were preincubated with or without specific
mAbs (anti-CD11a, 2D7, anti-CD11b, M1/70
or 5C6, anti-CD11c, HL3, anti-CD18, C17/16,
control A95-1), and incubated with CyaA at the
fixed concentration of 5 mg/ml. Values of DMFI
obtained for CyaA binding on cells treated with
specific mAbs were normalized as a percentage
of the DMFI values obtained for CyaA binding
without mAb.1039 Guermonprez et al.
and J774A.1 cells was correlated with cell surface expres-
sion of the integrin CD11b/CD18.
CyaA Saturable Binding Is Specifically Blocked by Anti-
CD11b mAbs. Next, we examined if CD11b/CD18
could be directly involved in the binding of CyaA to the
cells expressing this integrin. As shown in fluorescence his-
tograms in Fig. 2 a, b, and c, preincubation of D1 cells with
the anti-CD11b M1/70 mAb strongly and specifically in-
hibited the binding of CyaA to the cell surface. Then we
performed a quantitative analysis of this inhibition by cal-
culating the percentage of MFI values in the absence or
presence of mAbs at a fixed (Fig. 2 g) or varying (Fig. 2 d)
concentration(s) of CyaA. Inhibition of CyaA binding to
D1 cells obtained with the M1/70 anti-CD11b mAb was
almost total at most CyaA concentrations tested (Fig. 2 d).
This inhibition was specific since anti-CD11a, -CD11c,
-CD18 mAbs, or a control mAb did not affect CyaA bind-
ing (Fig. 2 g). A second anti-CD11b mAb (clone 5c6) also
inhibited binding of CyaA (Fig. 2 g). Similar results were
obtained with FSDCs, an immature dendritic cell line ex-
pressing CD11b (Fig. 2, e and h), and the J774A.1 mac-
rophage cell line (Fig. 2, f and i).
To examine whether CyaA could similarly interact with
human CD11b, CyaA binding studies were performed on
human neutrophils, whose high expression of CD11b is
well established. Since high background fluorescence was
obtained after incubation of human myeloid cells with the
anti-CyaA rabbit Abs (data not shown), we set up an alter-
nate binding assay. A detoxified form of CyaA was specifi-
cally biotinylated on a unique cysteine residue genetically
introduced within its catalytic domain. Using streptavidin-
PE, we were able to detect CyaA binding to neutrophils
(Fig. 3). Preincubation of neutrophils with the anti-CD11b
mAbs 44 or M1/70 led to a complete or partial inhibition
of the binding of CyaA, respectively (Fig. 3, b and d). Un-
like the anti–murine CD18 mAb C71/16 that did not
block CyaA binding to murine cells, preincubation with
the human anti-CD18 TS/18 mAb led to a complete inhi-
bition of CyaA binding to human neutrophils (Fig. 3 b).
Preincubation of neutrophils with fMLP increased both
surface levels of CD11b (Fig. 3 e) and CyaA binding (Fig. 3
f). In agreement with these observations, CyaA was also
shown to bind to the human monocytic THP-1 cell line
(data not shown).
In conclusion, the CyaA binding to the surface of four
myeloid cell lines from both murine and human origin
(J774A.1, D1, FSDC, and THP-1) and freshly purified hu-
man neutrophils appears to be mainly mediated through
the CD11b/CD18 integrin.
CyaA-mediated cAMP Increase and Toxicity Are Specifically
Blocked by an Anti-CD11b mAb. To evaluate the physio-
logical relevance of CD11b/CD18-dependent CyaA bind-
ing, we studied the effect of blocking mAbs on the cytotox-
icity of CyaA. First we measured the amount of cAMP
produced in J774A.1 cells exposed to CyaA in the presence
of various mAbs. As shown in Fig. 4 A, the increase in the
intracellular cAMP content induced by CyaA was totally
abolished when cells were preincubated with the M1/70
anti-CD11b mAb. The C17/16 anti–murine CD18 mAb
that did not block CyaA cell binding (Fig. 2) had no effect
on the intracellular cAMP content of CyaA-treated cells
(Fig. 4 A). Thus, these data strongly suggest that the increase
in intracellular cAMP induced by CyaA is dependent on the
interaction of the toxin with CD11b. To further analyze the
requirement of this molecule for the toxicity of CyaA, we
evaluated the effect of mAbs specific for the different chains
of the b2 integrin family on CyaA-mediated cell lysis. Fig. 4
Figure 3. CyaA binding to human neutrophils is blocked by anti-
CD11b and anti-CD18 mAbs and is correlated to CD11b surface levels.
(a–c) Fluorescence histograms of freshly purified neutrophils preincubated
with medium alone (a), the anti-CD11b mAb 44 (b), or an isotype-
matched control mouse mAb (c), then incubated with (gray) or without
(white) biotinylated detoxified CyaA (5 mg/ml), and revealed by strepta-
vidin-PE. Cell number is plotted against log of PE fluorescence. (d) Effect
of specific mAbs on CyaA binding to neutrophils (anti-CD11b, 44 or
M1/70, anti-CD18, TS/18, control mouse IgG2a, control rat IgG2b,
A95-1). Freshly purified neutrophils were preincubated with or without
specific mAbs and incubated with biotinylated detoxified CyaA. Values of
DMFI obtained for CyaA binding on cells treated with specific mAbs
were normalized as a percentage of the DMFI values obtained for CyaA
binding without mAb. (e and f) Neutrophil activation triggers the in-
crease of both CD11b surface level and CyaA binding. Fluorescence his-
tograms of freshly purified neutrophils that were pretreated or not with 2
mM fMLP for 30 min at 378C and then were stained with the anti-
CD11b mAb (e) or 15 mg/ml biotinylated detoxified CyaA (f).1040 CyaA from Bordetella pertussis Binds to Cells via CD11b/CD18
B shows that anti-CD11b mAb dramatically reduced the
cell lysis induced by CyaA in J774A.1 (88% inhibition). The
cell death induced by CyaA was unaffected by preincuba-
tion with mAbs that did not block toxin binding to cells
(anti-CD11a, -CD11c, -CD18, or a control mAb).
Collectively, these data indicate that CyaA binding
through CD11b is strictly required for CyaA-mediated
toxicity in J774A.1 cells.
Transfection of CHO Cells with CD11b/CD18 Confers
Sensitivity to CyaA. To confirm the role of CD11b in
CyaA binding, we used CHO cells transfected with the
human integrins CD11b/CD18, CD11c/CD18, or mock
transfected (vector alone). As shown in Fig. 5 A, CyaA
bound at 378C to all of these three cell lines. However,
CyaA binding was efficient and saturable in CHO cells ex-
pressing CD11b/CD18 but not in CD11c/CD18 or
mock-transfected cells. The affinity of CyaA for CD11b/
CD18 transfected cells was in the nanomolar range (Kd =
0.7 6 0.09 nM). At 48C, the efficiency of CyaA binding
was reduced compared with the binding at 378C (Fig. 5 B).
At this temperature, the difference in CyaA-binding capa-
bility between CD11b/CD18 transfected cells and the two
other cell lines was even more pronounced.
Since we found that CD11b was required for CyaA-
mediated toxicity in J774A.1, we wondered if CD11b ex-
pression was sufficient to confer a CyaA-sensitive pheno-
type to transfected CHO cells. In line with previous reports
(42), CyaA induced a significant increase in intracellular
cAMP in CHO cells transfected with CD11c/CD18 or in
control mock-transfected cells, but only at high concentra-
tions of toxin (5 mg/ml; Fig. 5 C). In contrast, CyaA in-
creased the intracellular level of cAMP in CD11b/CD18
transfected CHO cells even at the lowest concentration
studied (0.05 mg/ml). Moreover, the cAMP production in
response to 5 mg/ml CyaA was four to five times more ele-
vated in CD11b/CD18 transfected cells compared with
CD11c/CD18 or mock-transfected cells.
We also evaluated the role of CD11b/CD18 in CyaA-
mediated cell death. As shown in Fig. 5 D, .50% of CHO
transfected with CD11b/CD18 were killed after a 4-h in-
cubation with 5 mg/ml of CyaA, whereas CD11c/CD18 or
mock-transfected cells were not affected by this treatment.
Figure 4. Intracellular cAMP increase and cell death mediated by CyaA
are specifically blocked by an anti-CD11b mAb in J774A.1 cells. (A) Ef-
fect of specific mAbs on intracellular cAMP accumulation. J774A.1 cells
were preincubated at 48C for 1 h with or without 10 mg/ml of specific
mAbs (anti-CD11b, M1/70 or anti-CD18, C17/16) and then incubated
at 378C for 20 min with 5 mg/ml CyaA and with 10 mg/ml mAbs if
present during the preincubation. Intracellular cAMP contents were de-
termined as described in Materials and Methods. (B) Effect of specific
mAbs on CyaA-mediated cell death. J774A.1 cells were preincubated at
48C for 1 h with medium alone or with 10 mg/ml of specific mAbs (anti-
CD11a 2D7, anti-CD11b M1/70, anti-CD11c HL3, anti-CD18 C71/16,
control 2.4G2). Then, they were incubated at 378C for 2 h with 0.5 mg/
ml CyaA and with 10 mg/ml of specific mAbs when added during the
preincubation. Cell lysis was determined by LDH release using the Cyto-
tox 96™ assay.
Figure 5. CHO cells bind CyaA and become sensitive to CyaA when
transfected with CD11b, but not with CD11c. (A and B) CyaA binding
at the surface of CHO transfectants. CHO cells transfected with human
CD11b/CD18, human CD11c/CD18, or mock-transfected were incu-
bated with various doses of CyaA for 20 min at 378C (A) or 48C (B). Sur-
face-bound CyaA was detected with biotinylated anti-CyaA polyclonal
Abs, revealed by streptavidin-PE, and detected by flow cytometry on liv-
ing cells. Binding is expressed as DMFI = (MFI value of cells incubated
with CyaA) 2 (MFI of cells without CyaA). (C) Intracellular cAMP ac-
cumulation in CHO transfectants. CHO cells transfected with human
CD11b/CD18, human CD11c/CD18, or mock-transfected were incu-
bated with or without CyaA for 20 min at 378C. Intracellular cAMP con-
tents were determined as described in Materials and Methods. (D) Cell ly-
sis in CHO transfectants. CHO cells transfected with human CD11b/
CD18, human CD11c/CD18, or mock-transfected were incubated with
5 mg/ml CyaA for 4 h at 378C. Cell lysis was determined by LDH release
using the Cytotox 96™ assay.1041 Guermonprez et al.
Altogether, these results clearly established that expression
of human CD11b/CD18 integrin is sufficient for efficient
binding of CyaA and subsequent toxicity in CHO cells.
Role of Divalent Cations in CyaA Binding to Cells. Since
the interaction of integrins with their various ligands is
known to be promoted by divalent cations (43), we tested
the binding of CyaA to CD11b1 cells in the presence of ei-
ther Mg21 alone, Ca21 alone, or both Ca21 and Mg21 (Fig.
6 A). Our results clearly demonstrate that Ca21 is strictly
required for CyaA binding to murine D1 and J774 cells and
to human neutrophils. Strikingly, unlike other CD11b
ligands, CyaA binding does not require Mg21. In agree-
ment with this observation, divalent cation depletion (in
the presence of EDTA) or selective Ca21 depletion (in the
presence of EGTA) abrogated CyaA binding in the
DMEM medium containing both Ca21 and Mg21 (Fig. 6
B). Thus, Ca21 is necessary and sufficient to allow the in-
teraction of CyaA with CD11b1 cells.
Discussion
Unlike other toxins, CyaA has been considered for a
long time as independent of any receptor binding. This was
based on the observations that CyaA can intoxicate a wide
variety of cell lines from various origins (14) and binds to
Jurkat cells and sheep erythrocytes in a nonsaturable fashion
(44). These observations established that nonspecific ad-
sorption of CyaA to lipid membranes leads to some translo-
cation of the catalytic domain into the cytosol. However,
they did not rule out the existence of a specific receptor.
Indeed, in vivo studies showed that during murine respira-
tory infection with Bordetella species, CyaA specifically de-
stroyed leukocytes (especially macrophages) without dra-
matically damaging epithelial cells (6, 31). In this study, we
hypothesized that this specificity might be linked to the rec-
ognition of a receptor specifically expressed by certain leu-
kocytes. We showed, using myeloid cell lines, that the
binding and the toxic properties of CyaA are dependent on
its interaction with the integrin CD11b/CD18. Efficient
and saturable binding of CyaA correlates with the expres-
sion of CD11b and is fully and specifically blocked by anti-
CD11b mAbs. Moreover, expression of CD11b/CD18 in
CHO cells dramatically enhances the binding of CyaA and
its cytotoxicity. Our results are the first evidence supporting
the interaction of CyaA with a cell-surface molecule specif-
ically expressed on leukocytes. The nearly complete inhibi-
tion of CyaA binding by anti-CD11b mAbs and anti-CD18
for human cells suggests that CD11b/CD18 is the main re-
ceptor for CyaA in the cell lines tested. The lack of efficient
binding to CD11c/CD18 transfectants, or CD11a/CD18
expressing cells such as EL4 or LB27.4, also suggests that
CD11b/CD18 is the only integrin of the b2 family in-
volved in the binding of CyaA to the target cells. However,
the weak binding of CyaA to LB27.4 cells may suggest an
ancillary role for CD11d (45) or another surface ligand.
This study clearly shows that the interaction of CyaA
with CD11b1 cells is strictly dependent on Ca21, as could
be expected since CyaA is a calcium-binding protein (18).
Ca21 ions bind to the RTX repeat motifs with a weak af-
finity and trigger a conformational change that allows the
toxin to bind to target cell membranes and to translocate its
catalytic domain into the cytosol (13, 18, 22). More surpris-
ingly, our study also established that the binding of CyaA to
CD11b1 cells is independent of Mg21. To our knowledge,
most known ligands (fibrinogen, iC3b, intercellular adhe-
sion molecule 1) of CD11b/CD18 bind to the I domain of
CD11b in a Mg21 (or Mn21) dependent fashion (43).
Structural and functional analyses have shown that the inte-
grin I domain contains a Mg21/Mn21 coordination site at its
surface (MIDAS) that is critical for ligand binding (46–48).
Therefore, CyaA might be the first example of a novel class
of Mg21 independent CD11b ligand. These results also sug-
gest that CyaA binding to CD11b/CD18 might occur in-
dependently of the CD11b I domain. Indeed, regions out-
side the I domain have been shown to contribute partially
to the binding of some proteinaceous ligands like factor X
(49). Moreover, CD11b/CD18 displays other binding sites
like the well-characterized lectin-like binding site involved
in the binding of b-glucans (50) and possibly in the lateral
association of CD11b/CD18 with FcgRIII (51).
Experiments are currently underway to map the regions
of interaction between CyaA and CD11b/CD18. At
present, we can only exclude the possibility of CyaA bind-
ing via an arginine-glycine-aspartate motif since CyaA does
not contain such a sequence and an argine-glycine-aspar-
tate peptide does not inhibit CyaA binding to CD11b1
cells (data not shown).
In line with previous studies (for a review, see reference
14), we observed a detectable binding of CyaA to all cell
Figure 6. Ca21 is necessary and suffi-
cient for CyaA binding to CD11b1 cells.
(A) D1 or J774 cells, or freshly purified
neutrophils were washed twice with
Tris-buffered saline and then incubated with Tris-buffered saline supple-
mented with either 5 mM EDTA (EDTA), 2 mM Mg21 and 100 mM
EGTA (Mg), 2 mM Ca21 (Ca), or 2 mM Ca21 and 2 mM Mg21 (Ca 1
Mg). After the addition of 10 mg/ml biotinylated detoxified CyaA, all
samples were incubated for 20 min at 48C. Bound CyaA was detected by
streptavidin-PE as described above, and results are expressed as a percent-
age of CyaA binding in the presence of 2 mM Ca21 and 2 mM Mg21. (B)
D1 cells were incubated in the presence of DMEM alone, DMEM and 5
mM EDTA, or DMEM and 5 mM EGTA, and stained with biotinylated
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lines tested. Furthermore, at high concentrations CyaA
triggered a small but detectable cAMP increase in mock-
transfected CHO cells that is not associated with cell lysis.
Thus, although at high concentration CyaA can bind and
enter into a wide variety of cell lines, at low concentrations
only CD11b-expressing cells will be intoxicated by CyaA.
Previous studies, performed mainly on erythrocytes (de-
void of CD11b) led to a two-step model for translocation
of CyaA across membranes (22). First CyaA binds to the
membrane via its COOH-terminal moiety without any re-
ceptor involvement, then the NH2-terminal catalytic do-
main translocates across the plasma membrane to the cyto-
sol (22), coincidentally with a conformational change
triggered by Ca21 binding to the RTX repeats located in
the COOH-terminal domain of CyaA (18). The interac-
tion between CyaA and CD11b/CD18 could favor the
membrane insertion of CyaA, or, alternatively, CyaA may
bind first to lipid membrane, and then CD11b may partici-
pate in stabilizing its interaction with membranes, allowing
a more efficient intoxication.
The ability to translocate directly across the plasma
membrane is a peculiarity of CyaA, which is considered to
be the only toxin known to reach the cytoplasm without
going through vesicular trafficking. Indeed, after binding to
a specific receptor at the cell surface, other toxins acting on
cytosolic targets are taken up together with their receptor
by endocytic pathways. Some toxins like the Bacillus anthra-
cis lethal factor or the diphtheria toxin translocate into the
cytosol from acidic vesicles of the endocytic pathway. Oth-
ers like the Shiga toxin, the cholera toxin, or the Pseudomo-
nas exotoxin A are routed via a retrograde endocytic path-
way to the endoplasmic reticulum from which they reach
the cytosol (52). Unlike CD11a/CD18, which does not
undergo endocytosis efficiently and may retain RTX toxins
at the membrane of the cell, CD11b/CD18 can be inter-
nalized by endocytosis (53, 54). This calls into question the
physiological relevance of the current model of direct
translocation of CyaA from the plasma membrane to the
cytosol. Current experiments are in progress to determine
whether CyaA is taken up by endocytosis together with
CD11b and to characterize the precise location of the
membrane translocation events.
Binding of CyaA to a member of the b2 integrin family
is reminiscent of the behavior of other RTX toxins which
were recently found to interact with these molecules (32–
34). The E. coli HlyA, which shares a strong homology
with CyaA, forms cationic pores at the plasma membrane.
HlyA exhibits a specificity for leukocytes but only at a low
concentration (55). This relative specificity was shown to
be mediated by its interaction with the integrin CD11a/
CD18 (32). Besides that, Actinobacillus actinomycetemcomitans
and Pasteurella haemolytica leukotoxins (LtxA and LktA, re-
spectively) are RTX toxins specific for human and bovine
leukocytes, respectively, but also interact with CD11a/
CD18 (32–34). Despite its strong homology with HlyA,
CyaA recognizes another b2 integrin (CD11b/CD18)
whose cellular distribution is more restricted. Indeed,
CD11b is expressed mostly on macrophages, neutrophils,
and dendritic cells, but not on the majority of T and B
cells, whereas CD11a is expressed on all leukocytes includ-
ing T and B lymphocytes.
The restricted specificity is in agreement with the effect
of CyaA in the early phases of infection on bactericidal
phagocytes such as macrophages (6, 29) and neutrophils
(31). Such specific targeting of CyaA toxicity to CD11b-
expressing cells may represent an escape mechanism against
the early steps of the innate immune response. Indeed, this
could allow the specific elimination of these cells (6, 29,
30) and/or eventually the inhibition of their oxidative mi-
crobicidal functions in the case of sublethal intoxication
(13, 25, 26). The killing of lung dendritic cells, which are
known to express CD11b, may also have indirect effects on
the development of protective adaptative responses. Fi-
nally, the specificity of CyaA for CD11b1 cells reinforces
the hypothesis that the effect of CyaA on immune effector
cells participates in the inhibition of antibacterial responses
to bystander pathogens during B. pertussis infection as orig-
inally proposed by Confer and Eaton (13).
The filamentous hemagglutinin (FHA) of B. pertussis has
also been shown previously to interact with CD11b/CD18
(56) leading to the internalization of a subset of bacteria
during the course of infection (57). Moreover, FHA also
interacts with a complex containing the leukocyte response
integrin and the integrin-associated protein CD47 that is
known to upregulate the expression of CD11b/CD18 (58).
It is striking that such different factors, both in terms of
structure and function, target the same molecule on leuko-
cytes. One could imagine that they may cooperate to effi-
ciently deplete the CD11b/CD18-expressing leukocytes.
FHA may, for example, act first to bind to cells and facili-
tate the interaction of CyaA with this receptor. Such a hy-
pothesis was suggested previously in a study showing that
both CyaA and FHA are necessary to inhibit monocyte
function (59). Therefore, the interplay between FHA and
CyaA remains to be determined.
This selective binding of CyaA to CD11b-expressing
cells might be exploited to specifically target this particular
subset of cells. Detoxified mutants of CyaA might be used
to deliver pharmacologically active molecules to CD11b1
cells, without noticeably affecting other cell types. In fact,
we recently developed such an approach by genetic inser-
tion into detoxified CyaA of viral (60) or tumoral peptides
(61). Once delivered into the cytosol of APCs and after
proteasome-dependent intracellular processing, the inserted
epitopes are presented by MHC class I molecules to CD81
T cells (62) and in vivo, stimulate protective CTL re-
sponses against viral challenge (60) or tumor graft (61). The
present results highlight the strong potential of delivery
vectors based on such CyaA detoxified mutants.
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